Stocky turns companies like Erasca, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Erasca, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026More cash helps the company fund drug development, but existing shareholders own a smaller piece.
The final price shows what investors will pay; lower than hoped means less money per share for the company.
Companies sell new stock to fund operations; investors should watch how much existing shares get diluted.
Positive drug trial results can boost stock price if the medicine works and reaches patients.
Directors guide the company; auditors check finances honestly so investors know the numbers are real.
Quarterly earnings show if the company is spending wisely and moving toward profitability.
Stocky reads Erasca, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Erasca, Inc.'s most recent tracked filing was a 8-K on 14 Jul 2026: Raises $517 million selling 31.4 million shares.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.